A German Phase 2b RCT published March 18 in JAMA Psychiatry put numbers to what the psychedelic therapy field had long avoided confronting directly: psilocybin's response rates (17.0% at 25 mg, 12.5% at 5 mg) were statistically indistinguishable from active placebo (10.6%, p=.19) in 144 treatment-resistant depression patients across a triple-blinded, multi-center trial — the EPISODE study. Published alongside it in the same journal, a UCSF/Imperial College meta-analysis provided the structural explanation: 90-95% of psychedelic trial participants correctly identify whether they received the drug, meaning psychedelic trials are effectively always unblinded. When benchmarked against open-label antidepressants under equivalent unblinding conditions, no statistically significant advantage for psychedelic therapy remains. MIT Technology Review synthesized both papers for mainstream readership on March 20.

Four days later, the University of Sussex published the first neuroimaging evidence that controlled breathwork produces altered states of consciousness measurable via neural complexity metrics at levels comparable to psychedelics. The same week that psilocybin's clinical evidence base was put under scrutiny, a non-pharmacological pathway to neurophysiologically equivalent states received peer-reviewed validation.

This tension is not coincidental — it reflects a field sorting itself out. The therapeutic container (the preparation protocol, the digital companion, the integration framework, the practitioner training platform) has been treated as a delivery mechanism for the drug. The blinding meta-analysis makes the case that the container may be the active ingredient. Compass Pathways confirmed its COMPASS digital companion is core to its commercial model as it prepares an NDA. Fireside Project launched Lucy, an AI training platform for psychedelic practitioners — a direct bet on the therapeutic container as a defensible asset. On the same day the EPISODE results published, Massachusetts advanced two psychedelic therapy pilot bills, demonstrating that state-level policy operates on its own timeline independent of clinical trial outcomes.